"2024 ENMC diagnostic criteria have numerous criteria but are summarised as fitting one of the following 17:"
Expected headings
"Associations"
"Fluoroscopy"
"History and prognosis"
"finger flexors (e.g. flexor digitorum profundus, flexor pollicis longus)"
"There is no disease-modifying treatment for inclusion body myositis. The disease is generally unresponsive to corticosteroids and immunosuppressive drugs 7. There may be some evidence suggesting a slight, short-lasting benefit from intravenous immunoglobulin therapy, particularly in patients with dysphagia. Thus, management is essentially supportive (physical therapy to improve mobility, etc.)."
"Inclusion body myositis is a slow progressive disease with significant morbidity; ~30% (range 12-47%) of patients are wheelchair-bound 17. The most common cause of death is respiratory failure and pneumonia 17."